Chronic Myeloid Leukemia (CML) is a stem cell disease sustained by a rare population of quiescent cells which are to some extent resistant to tyrosine kinase inhibitors (TKIs). BCR-ABL oncogene activates multiple cross-talking signal transduction pathways (STP), such as RAS/MEK/ERK, PI3K/Akt, Wnt and STAT5, contributing to abnormal proliferation of clonal cells. From this perspective, the aim of this study was to analyze the expression and activation profile of STP involved in the mechanisms of cell proliferation/quiescence and survival of the progenitor CD34+ cells from chronic phase (CP) CML. Our results showed that CP-CML CD34+ progenitors were characterized by significant lower phosphorylation of proteins involved in the regulation of growth and cell survival, such as tyrosine kinases of the Src family and members of STAT family, and by a significant higher phosphorylation of p53 (Ser15), compared to normal CD34+ cells from healthy donors. Consistent with these results, cell cycle analysis demonstrated that CP-CML CD34+ cells were characterized by higher percentage of cells in G0-phase compared to normal CD34+ cells. Analysis of expression profile on proteins involved in the apoptotic machinery revealed that, in addition, CD34+ cells from CP-CML were characterized by a significant lower expression of catalase and higher expression of HSP27 and FADD. In sum, we report that CD34+ cells from CP-CML are characterized by a proteomic and phospho-proteomic profile that promotes quiescence through the inhibition of proliferation and the promotion of survival. This differential signaling activation network may be addressed by novel targeted therapies aimed at eradicating CML stem cells.

Chronic Myeloid Leukemia (CML) is a stem cell disease sustained by a rare population of quiescent cells which are to some extent resistant to tyrosine kinase inhibitors (TKIs). BCR-ABL oncogene activates multiple cross-talking signal transduction pathways (STP), such as RAS/MEK/ERK, PI3K/Akt, Wnt and STAT5, contributing to abnormal proliferation of clonal cells. From this perspective, the aim of this study was to analyze the expression and activation profile of STP involved in the mechanisms of cell proliferation/quiescence and survival of the progenitor CD34+ cells from chronic phase (CP) CML. Our results showed that CP-CML CD34+ progenitors were characterized by significant lower phosphorylation of proteins involved in the regulation of growth and cell survival, such as tyrosine kinases of the Src family and members of STAT family, and by a significant higher phosphorylation of p53 (Ser15), compared to normal CD34+ cells from healthy donors. Consistent with these results, cell cycle analysis demonstrated that CP-CML CD34+ cells were characterized by higher percentage of cells in G0-phase compared to normal CD34+ cells. Analysis of expression profile on proteins involved in the apoptotic machinery revealed that, in addition, CD34+ cells from CP-CML were characterized by a significant lower expression of catalase and higher expression of HSP27 and FADD. In sum, we report that CD34+ cells from CP-CML are characterized by a proteomic and phospho-proteomic profile that promotes quiescence through the inhibition of proliferation and the promotion of survival. This differential signaling activation network may be addressed by novel targeted therapies aimed at eradicating CML stem cells.

Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients / Ricciardi, Maria Rosaria; Salvestrini, Valentina; Licchetta, Roberto; Mirabilii, Simone; Forcato, Mattia; Gugliotta, Gabriele; Salati, Simona; Castagnetti, Fausto; Rosti, Gianantonio; Breccia, Massimo; Alimena, Giuliana; Manfredini, Rossella; Bicciato, Silvio; Lemoli, Roberto Massimo; Tafuri, Agostino. - In: ONCOTARGET. - ISSN 1949-2553. - 9:31(2018), pp. 21758-21769. [10.18632/oncotarget.24938]

Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients

Forcato, Mattia;Salati, Simona;Manfredini, Rossella;Bicciato, Silvio;Lemoli, Roberto Massimo;
2018

Abstract

Chronic Myeloid Leukemia (CML) is a stem cell disease sustained by a rare population of quiescent cells which are to some extent resistant to tyrosine kinase inhibitors (TKIs). BCR-ABL oncogene activates multiple cross-talking signal transduction pathways (STP), such as RAS/MEK/ERK, PI3K/Akt, Wnt and STAT5, contributing to abnormal proliferation of clonal cells. From this perspective, the aim of this study was to analyze the expression and activation profile of STP involved in the mechanisms of cell proliferation/quiescence and survival of the progenitor CD34+ cells from chronic phase (CP) CML. Our results showed that CP-CML CD34+ progenitors were characterized by significant lower phosphorylation of proteins involved in the regulation of growth and cell survival, such as tyrosine kinases of the Src family and members of STAT family, and by a significant higher phosphorylation of p53 (Ser15), compared to normal CD34+ cells from healthy donors. Consistent with these results, cell cycle analysis demonstrated that CP-CML CD34+ cells were characterized by higher percentage of cells in G0-phase compared to normal CD34+ cells. Analysis of expression profile on proteins involved in the apoptotic machinery revealed that, in addition, CD34+ cells from CP-CML were characterized by a significant lower expression of catalase and higher expression of HSP27 and FADD. In sum, we report that CD34+ cells from CP-CML are characterized by a proteomic and phospho-proteomic profile that promotes quiescence through the inhibition of proliferation and the promotion of survival. This differential signaling activation network may be addressed by novel targeted therapies aimed at eradicating CML stem cells.
24-apr-2018
9
31
21758
21769
Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients / Ricciardi, Maria Rosaria; Salvestrini, Valentina; Licchetta, Roberto; Mirabilii, Simone; Forcato, Mattia; Gugliotta, Gabriele; Salati, Simona; Castagnetti, Fausto; Rosti, Gianantonio; Breccia, Massimo; Alimena, Giuliana; Manfredini, Rossella; Bicciato, Silvio; Lemoli, Roberto Massimo; Tafuri, Agostino. - In: ONCOTARGET. - ISSN 1949-2553. - 9:31(2018), pp. 21758-21769. [10.18632/oncotarget.24938]
Ricciardi, Maria Rosaria; Salvestrini, Valentina; Licchetta, Roberto; Mirabilii, Simone; Forcato, Mattia; Gugliotta, Gabriele; Salati, Simona; Castagnetti, Fausto; Rosti, Gianantonio; Breccia, Massimo; Alimena, Giuliana; Manfredini, Rossella; Bicciato, Silvio; Lemoli, Roberto Massimo; Tafuri, Agostino
File in questo prodotto:
File Dimensione Formato  
Ricciardi et al_Oncotarget_2018.pdf

accesso aperto

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 2.01 MB
Formato Adobe PDF
2.01 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1174070
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 3
  • ???jsp.display-item.citation.isi??? ND
social impact